{
  "title": "Paper_31",
  "abstract": "pmc Mol Nutr Food Res Mol Nutr Food Res 379 blackwellopen MNFR Molecular Nutrition & Food Research 1613-4125 1613-4133 pmc-is-collection-domain yes pmc-collection-title Wiley Open Access Collection PMC12490186 PMC12490186.1 12490186 12490186 40509652 10.1002/mnfr.70133 MNFR70133 1 Research Article Research Article Protective Properties of the White Button Mushroom, Agaricus bisporus Dempsey Elaine  1 Walsh Aaron M.  2 Yadav Supriya  3 Wilson Jude https://orcid.org/0009-0003-0757-3178  3 Sheedy Frederick J. https://orcid.org/0000-0003-2645-8493  2 Corr Sinead C. https://orcid.org/0000-0001-9930-5039  1  4 scorr@ucc.ie   1 School of Genetics & Microbiology Trinity College Dublin Dublin Ireland   2 School of Biochemistry & Immunology Trinity College Dublin Dublin Ireland   3 MBio, Monaghan Mushrooms Tyholland, Co. Monaghan Ireland   4 School of Microbiology and APC Microbiome Ireland University College Cork Cork Ireland 12 6 2025 10 2025 69 19 498134 10.1002/mnfr.v69.19 e70133 07 3 2025 13 11 2024 08 5 2025 02 10 2025 03 10 2025 03 10 2025 ¬© 2025 The Author(s). Molecular Nutrition & Food Research https://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ ABSTRACT Previous work demonstrated the promising immunomodulatory potential of a naturally derived whole mushroom powder (WMP) from the white button mushroom, Agaricus bisporus Allobaculum In this study, whole mushroom powder (WMP) from white button mushrooms was tested for gut health benefits. In vitro digested WMP (IVD‚ÄêWMP) could reduce the permeability of a gastrointestinal cell layer. In mouse studies, WMP was tested as a preventative and a treatment for dextran sulfate sodium (DSS) induced colitis. WMP could improve recovery, reduce inflammation and oxidative stress, and promoted healthier gut bacteria. This suggests WMP could help support digestive wellness and recovery from gut inflammation. colitis inflammation microbiome mushroom oxidative stress Irish Research Council Enterprise Partnership Scheme (Postdoctoral) EPSPD/2022/130 Science Foundation Ireland Frontiers for the Future Programme 19/FFP/6499 pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes source-schema-version-number 2.0 cover-date October 2025 details-of-publishers-convertor Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:02.10.2025  E. Dempsey A. M. Walsh S. Yadav J. Wilson F. J. Sheedy S. C. Corr Protective Properties of the White Button Mushroom, Agaricus bisporus Molecular Nutrition & Food Research 69 19 2025 e70133 10.1002/mnfr.70133 PMC12490186 40509652  Funding Abbreviations 16S rRNA 16S ribosomal RNA ANOVA analysis of variance DAI disease activity index DSS dextran sulfate sodium EGFR epithelial growth factor receptor H&E hematoxylin and eosin IBD inflammatory bowel disease IVD‚ÄêWMP in vitro digested whole mushroom powder MDA malondialdehyde MPO myeloperoxidase MUC mucin ROS reactive oxygen species SOD superoxide dismutase TNF tumor necrosis factor WMP whole mushroom powder ZO zonula occludens 1 Introduction Mushrooms have been celebrated for millennia for their culinary, nutritional, and medicinal properties. The ancient Egyptians, Romans, and Mayans revered mushrooms as ‚Äúimmortality food,‚Äù ‚Äúfood of the Gods,‚Äù and ‚Äúflesh of the Gods,‚Äù respectively [ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 15 16 17 18 19 Despite representing one of the most widely consumed mushroom species worldwide, the health‚Äêpromoting effects of the white button mushroom ( Agaricus bisporus 20 A. bisporus 21 22 A. bisporus 22 A. bisporus 50 23 24 A. bisporus 25 26 A. bisporus 2 2 A. bisporus 27 A. bisporus 28 Agaricus 29 Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is a chronic inflammatory condition of the gastrointestinal tract characterized by a dysregulated immune response, mucosal barrier disruption, and gut microbiota dysbiosis [ 30 31 32 33 34 35 This study further explores the potential of A. bisporus A. bisporus A. bisporus 2 Experimental Section 2.1 Mushroom Powder Mushroom powder used in this study was from A. bisporus 36 23 2.2 Dosage Information Dosage was determined as described previously [ 23 2.3 Cell Culture Caco‚Äê2 or HT‚Äê29‚ÄêMTX cells were maintained at 37¬∞C with 5% CO 2 4 2.4 In Vitro Permeability Assay Integrity of the cell monolayer was assayed by measuring permeability to FITC dextran as previously described [ 37 Œª EX Œª EM 2.5 In Vivo Studies C57BL/6 mice were maintained in ventilated cages at 21 ¬± 1¬∞C, humidity 50% ¬± 10%, and with a 12¬†h‚Äêlight/12¬†h‚Äêdark cycle under specific pathogen‚Äêfree conditions according to Irish and European Union regulations. Food and water were monitored and available ad libitum throughout experiments unless otherwise stated. All animal experiments were carried out according to the recommendations of Trinity College Dublin's Animal Research Ethics Committee and the Irish Health Products Regulatory Authority, the competent authority responsible for the implementation of Directive 2010/63/EU on the protection of animals used for scientific purposes in accordance with the requirements of the S.I No 543 of 2012. 2.6 DSS‚ÄêInduced Colitis The DSS‚Äêinduced colitis model is widely used as a robust model to study acute gastrointestinal inflammation similar to ulcerative colitis [ 38 39 1 2 TABLE 1 Scoring criteria for DAI. Score Weight loss (%) Stool consistency Blood 0 <1 Solid None 1 1‚Äì3 Soft, well‚Äêformed pellet Faint positive test 2 4‚Äì6 Softer, looser pellet Clear positive test 3 7‚Äì9 No form, diarrhea Visible red stool 4 >10 Liquid diarrhea Visible blood John Wiley & Sons, Ltd. 2.7 In Vivo Trial Schedules A pretreatment and a recovery trial were performed to determine the impact of WMP on the development of colitis and on recovery from established colitis, respectively. The experimental timeline for the pretreatment trial is illustrated in Figure 2A 2A 2E 2E 2.8 Mucosa‚ÄêBlood Flux FITC‚ÄêDextran Intestinal permeability in the pretreatment trial was assayed by translocation of FITC dextran 40¬†kDa (FD40; FD40S, Sigma‚ÄìAldrich). At 4¬†h before cull, mice received 80¬†mg/kg FD40 in 150¬†¬µL sterile PBS via oral gavage. Food was removed from the cage. Mice were culled by CO 2 g Œª EX Œª EM 2.9 Histology Sections from the distal colon of each mouse were obtained at the time of cull and subsequently fixed in 10% buffered formalin, embedded in paraffin wax, sliced on a microtome at 5¬†¬µm thickness, and placed on polysine adhesive slides. Slides were baked at 55¬∞C for 15¬†min. Hematoxylin and eosin (H&E) staining was performed to assess crypt length, tissue damage, and neutrophil infiltration. Alcian blue staining was performed to assess goblet cell loss. The staining steps were performed by a Leica Autostainer XL (Leica Microsystems). For H&E: xylene (x2), absolute alcohol (x2), tap water, hematoxylin (4¬†min), tap water, acid alcohol, tap water, eosin (2¬†min), tap water, absolute alcohol (x2), and xylene (x2). For Alcian blue: xylene (x2), absolute alcohol (x2), tap water, Alcian blue (pH 1; 5¬†min), tap water, nuclear fast red (5¬†min), tap water, absolute alcohol (x2), and xylene (x2). Tissue slices were imaged using an Olympus BX51 upright microscope. All slices were blind scored. For H&E sections, tissue damage and neutrophil infiltration were scored according to the scoring system as outlined in Table 2 40 TABLE 2 Scoring criteria for H&E. Inflammation severity Inflammation extent Crypt damage Percent involvement 0 None <10% Occasional cells in LP None None 1 Mild 10‚Äì25% Mucosa Basal 33% Up to 25% 2 Moderate 26%‚Äì50% Mucosa and submucosa Basal 66% 26%‚Äì50% 3 Severe 51%+ Transmural Crypt loss; surface epithelium present 51%‚Äì75% John Wiley & Sons, Ltd. 2.10 16S Sequencing and Analysis To determine the effects of WMP on the gut microbiota composition, 16S ribosomal RNA (16S rRNA) sequence analysis was performed on fecal samples from each trial. For the pretreatment trial, fecal samples were taken on Day 0 (start WMP), on Day 9 of WMP administration (start DSS), and on Day 16 (cull). For the recovery trial, samples were taken on Day 0 (start DSS), on Day 4 (end DSS, start WMP), and on Day 9 (cull). DNA extraction was performed using a Power‚Äêfecal‚Äêpro DNA extraction kit (51804, Qiagen) according to the manufacturer's protocol. DNA samples were quantified using a Qubit Broad Range DNA kit (Thermo Fisher) and diluted to 5¬†ng/¬µL. 16S metagenomics libraries were prepared using a miniaturization protocol based on the 16S metagenomic library preparation guide (Illumina). In brief, an Echo 525 (Beckman Coulter) was used to combine 0.5¬†¬µL DNA, 2.5¬†¬µL Kapa Hifi HotStart Ready Mix, and 1¬†¬µL of each of the primers (at 1¬†¬µM) in individual wells of a 96‚Äêwell plate. The plate was spun briefly, and amplification was performed according to the 16S metagenomic library preparation guide (Illumina) with 30 cycles in place of 25. Following amplification, the volume of each sample was increased to 20¬†¬µL using molecular grade water, and the samples were cleaned using a 0.8 X ratio of Ampure beads (Beckman Coulter) on a Beckman i7 (Beckman Coulter). The index PCR was again set up using the Echo 525 to dispense the reagents as follows: 1¬†¬µL cleaned PCR product, 2¬†¬µL Unique Duel Indices (IDT), 5¬†¬µL Kapa Hifi HotStart Ready Mix, and 2¬†¬µL molecular grade water. Plates were spun briefly, and PCR was performed as described in the 16S metagenomic library preparation guide (Illumina). Samples were then quantified using a Qubit High Sensitivity kit (Thermo Fisher) and pooled at equal concentration. The final pool was further cleaned using a 0.7 X ratio of Ampure beads (Beckman Coulter) and quantified using the Qubit High Sensitivity kit (Thermo Fisher). It was then sequenced on an Illumina NextSeq 2000 using NextSeq1000/2000 P1 Reagents (600 cycles) according to the manufacturer's guidelines (Illumina). Sequencing data was processed using QIIME 2 (version 2024.5.0) (RRID:SCR_021258) [ 41 42 p 2.11 Cytokine Quantification Cytokine concentration was determined using Invitrogen Uncoated ELISA kits (Thermo‚ÄêFisher) for mouse TNF (88‚Äê7324), IL‚Äê1ùõΩ (88‚Äê7013), IL‚Äê6 (88‚Äê7064), and IL‚Äê10 (88‚Äê7105) as per the manufacturer's protocol. 2.12 Oxidative Stress Assays Myeloperoxidase (MPO) activity in colon tissue was assessed using a slightly modified version of a previously described assay [ 43 2.13 RT‚ÄêqPCR RNA was isolated using the PureLink RNA mini kit (12183018A, Invitrogen) according to manufacturer's protocol, quantified using a Nanodrop 2000 UV‚Äêvisible spectrophotometer, and DNase‚Äêtreated according to manufacturer's protocol (EN0521, Thermo Scientific). Total RNA was reverse transcribed with a high‚Äêcapacity cDNA reverse transcription kit (4368814, Applied Biosystems), and cDNA was amplified using SYBR green‚Äêbased real‚Äêtime PCR (A25742, Applied Biosystems). SYBR RT‚ÄêqPCR results were analyzed by the CT method [2‚Äê(ŒîŒîCT)] to compare genes of interest to endogenous control genes. Primer sequences are listed in Table 3 TABLE 3 Primer sequences for RT‚ÄêqPCR. Forward primer Reverse primer Œ≤‚ÄêDefensin Human TCTGAGATGGCCTCAGGTGGT GTAAAGATCGGGGACGCAGAA Claudin1 Mouse ATGACCCCTTGACCCCCATC GGAGCAGGAAAGTAGGCACC Claudin1 Human GACCCTATGACCCCCAGTCAATG TTTTCGGGGACAGGAACAGC Claudin2 Mouse CCTGGGATTGTGCTTGAGGT TGACCCCCATCACCCACAGA Cadherin Mouse CCCAGAGACTGTGTGCATTT TGGCAATGGGTGAACCA TCA e‚ÄêCadherin Human CTGGTGGTCAACGCTCCTGAC CACCTGACCCTGTGTACTGGGT EGFR Mouse TCTTCAAGGAGTTGAAGTGTG TGTACGCTTTCGAACAATGT EGFR Human AGCGCTACCTTCTTCATTCAG CACGTGCTCCATGTCTTCTTT GAPDH Mouse TGTGTCCGTGGTGTGA TGGA CCTGCTTCACCACCTTCTTGAT GAPDH Human TCGACAGTCAGCCGCATCTT GCCCAATACGACCAAATCCGT MUC1 Mouse AAGCGTAGCCCTCATGAGGA GGGGTGACTTGCTCCTACAA Occludin Mouse TCCGTAGGGCCTTTTGAA GGTGCATATGATTGGGTTTG Occludin Human TCAGGGAATACCCACTACATT CAG CATCAGCAGCCACGTTACTCTTCAC ZO1 Human CCTGAGTTTGACAGTGGA GT GCTGAAGGACTACAGGAATAG ZO2 Mouse GCACCCTGACATCTATGCG CACTGCCGTAGCTTCCTCTG John Wiley & Sons, Ltd. 2.14 Statistical Analysis Data were analyzed and graphs were generated using GraphPad Prism v8.0 (GraphPad Software; RRID:SCR_002798), except for the microbiome data analysis described Section 2.10 t p 3 Results 3.1  A. bisporus To mimic digestion and to assess the impact of exposure of the gut epithelial barrier to digested WMP, an in‚Äêvitro digestate (IVD) of WMP (IVD‚ÄêWMP) was prepared. Pretreatment of Caco‚Äê2 cell monolayers with IVD‚ÄêWMP significantly reduced the translocation of FITC‚Äêdextran into the basal compartment of the transwell system (Figure 1A 1B S1A, D FIGURE 1  A. bisporus A. bisporus n p p t 3.2  A. bisporus Gastrointestinal inflammation and intestinal barrier dysfunction were modeled in mice by the administration of DSS via drinking water. Development of colitis was characterized by body weight loss, diarrhea, and bloody stools. In the pretreatment trial, A. bisporus 2A 2B 2B 2C 2D 2E 2F FIGURE 2 WMP gavage can reduce symptoms of DSS‚Äêinduced colitis in recovery. A. bisporus n p p p 3.3  A. bisporus Next, we assessed the impact of WMP on recovery from established colitis (Figure 2G‚ÄìL 2G 2H 2I 2J 2K 2L 3.4 Pretreatment With A. bisporus Histological analysis of colonic tissue architecture was performed by H&E staining to allow determination of histological score (Figure 3A S2A, B 3B 3C S2A, B 3A S2C 3B 3D 3E 3F 3D 3E 3F S3A‚ÄìD FIGURE 3 WMP has little effect on barrier integrity in DSS‚Äêinduced colitis. Distal colon tissue from pretreatment (A‚ÄìF) and recovery (G‚ÄìM) trials were fixed in formalin (10%), and 5¬†¬µm slices were histological analysis performed by the H&E method and the Alcian blue method. Representative images for both are shown (C, J; 100X magnification; scale bar = 200¬†¬µm). H&E images were scored for tissue damage and neutrophil infiltration to give a combined histology score (A, G). Alcian blue images were assessed for positive goblet cell stain (B, H). Additionally, in the recovery trial crypt length could be measured (I). RNA was extracted from distal colon tissue, and fold change in expression of genes related to barrier integrity was measured: occludin (D, K), claudin1 (E, L), EGFR (F, M). Data are mean ¬± SEM of n p p p 3.5  A. bisporus Histological analysis of colonic tissue architecture was performed following recovery from DSS‚Äêinduced colitis by H&E staining to allow determination of histological score (Figure 3G S2D, E 3H 3J S2D S2E 3G 3I 3H 3K 3L 3M S3E‚ÄìH 3.6  A. bisporus To further investigate the protective effects of A. bisporus 4A‚ÄìF S4A‚ÄìC 4A 4D 4B 4E 4C 4F S4C FIGURE 4 WMP has antiinflammatory effects in DSS‚Äêinduced colitis. Proximal and distal colon tissue from pretreatment (A‚ÄìF) and recovery (G‚ÄìL) trials were assayed by ELISA for cytokine levels of IL‚Äê1Œ≤ (A, D, G, J), TNF (B, E, H, K), and IL‚Äê10 (C, F, I, L). Data are mean ¬± SEM of n p p p 3.7  A. bisporus The antiinflammatory potential of A. bisporus 4G‚ÄìL 4G, J 4H S4D‚ÄìF 3.8  A. bisporus MPO activity, an indicator of neutrophil infiltration and oxidative stress, was assayed in proximal and distal colonic tissue. DSS administration increased MPO levels to similar levels in DSS‚Äêonly and WMP groups compared to healthy controls (Figure 5A 5D 5B 5E 5C 5F FIGURE 5 WMP has antioxidant effects in DSS‚Äêinduced colitis. Proximal and distal colon tissue from pretreatment (A‚ÄìF) and recovery (G‚ÄìL) trials were analyzed for levels of myeloperoxidase (MPO; A, D, G, J), malondialdehyde (MDA; B, E, H, K), and superoxide dismutase (SOD; C, F, I, L). Data are mean ¬± SEM of n p p p 3.9  A. bisporus MPO levels were significantly increased in the proximal colon of the DSS group compared to healthy controls but were not significantly elevated in the WMP group, potentially indicating an improved recovery in WMP‚Äêtreated mice (Figure 5G 5H 5I 5J 5K 5L 3.10  A. bisporus To determine any effect of WMP treatment on the gut microbiota and inflammation‚Äêinduced bacterial dysbiosis, we conducted 16S rRNA sequencing on fecal samples collected on Day 0, Day 9, and Day 16 in the pretreatment trial, with Day 9 (pre‚ÄêDSS), and Day 16 (post‚ÄêDSS) allowing analysis of WMP impact during both the pretreatment and DSS phases (Figure 6A‚ÄìF 6A 6B 6C A 6D‚ÄìF Alphaproteobacteria Parabacteroides S5 S5C S5B S5C FIGURE 6 WMP affects bacterial composition of the gut before DSS‚Äêinduced colitis. Fecal samples from pretreatment (A‚ÄìF) and recovery (G‚ÄìI) trials were analyzed by 16S rRNA sequencing. In the pretreatment trial, alpha diversity is estimated by Shannon index (A) and beta diversity by PCoA analysis (B) at Day 9 (pre‚ÄêDSS). Relative abundance of the Top 10 genera at Day 9 are displayed as stacked bar chart (C). Differences between the WMP pretreatment compared to vehicle control at Day 9 were revealed in abundance levels of A lphaproteobacteria Allobaculum Parabacteroides n p 3.11  A. bisporus To determine any effect of WMP treatment on the gut microbiota during the recovery period following DSS colitis, we conducted 16S rRNA sequencing on fecal samples from the recovery trial (Figure 6G‚ÄìI 6G 6H 6I 4 Discussion IBD is a chronic inflammatory condition of the digestive tract. Clinically, IBD is characterized by symptoms such as diarrhea, abdominal pain, rectal bleeding, weight loss, and fatigue. A key pathophysiological feature of IBD is increased intestinal permeability, often referred to as a ‚Äúleaky gut,‚Äù wherein the integrity of tight junctions within the intestinal epithelium is compromised, permitting the translocation of bacteria and antigens across the intestinal barrier and into the bloodstream, contributing to the pathogenesis of the disease [ 44 Recent research has highlighted the potential therapeutic benefits of polysaccharide extracts and products derived from various mushroom species in experimental models of IBD [ 19 45 47 A. bisporus 28 A. bisporus A. bisporus A. bisporus 23 We previously established an in vitro digestion procedure for WMP and confirmed that, following simulated digestion, IVD‚ÄêWMP retains its antiinflammatory properties in HEK dectin1 and HEK Toll‚Äêlike‚Äêreceptor‚Äê4 cell lines. Additionally, we demonstrated that intraperitoneal injection of IVD‚ÄêWMP is antiinflammatory in a mouse model of zymosan‚Äêinduced peritonitis [ 23 24 2 25 48 The current investigation employed a DSS‚Äêinduced colitis model in mice to evaluate the effects of A. bisporus WMP in both a preventative pretreatment context and a therapeutic recovery context. Due to ethical concerns, best practice guidelines, and project license limitations on repeated oral gavage in mice, it was not possible to administer WMP before, during, and following colitis in the same cohort of mice. However, we would hypothesize that this dosing schedule could contribute to further amelioration of the beneficial effects described, as WMP pretreatment seems to moderately decrease the severity of inflammation and, following inflammation, to speed repair of the tissue. Oral gavage was chosen as the most efficient way of ensuring that dosing of WMP was consistent for each mouse during the trial, particularly during and after the DSS period when food intake tends to be lower. However, this procedure can be stressful; therefore, long‚Äêterm effects of dietary WMP, both generally and pre‚Äê, during, and postinflammation could be studied in the future by incorporation into standard mouse chow. Although the effects were not significant, pretreatment with WMP consistently scored lower in stool and blood indices during the acute DSS colitis period and provided significant protection against colon shortening at the day of sacrifice. Histologically, no benefits of WMP pretreatment were observed in distal colon tissue in terms of tissue damage or cell infiltration; however, protection against goblet cell loss was observed. Additionally, there was a nonsignificant trend for intestinal permeability, as measured by FITC‚Äêdextran, to be protected by WMP pretreatment. When administered during the recovery phase following DSS‚Äêinduced colitis, WMP significantly lowered stool and DAI scores, and protected against colon shortening. Tissue histology showed improved crypt length measurements and a subtle, nonsignificant improvement in tissue damage and neutrophil infiltration scores in the WMP group, which may be suggestive of a boost to tissue repair. Intestinal epithelial barrier integrity is maintained via tight junction complexes, which are crucial for regulating transport across the epithelium. Disruption of tight junction proteins by dysregulated protein expression has been implicated in the pathogenesis of IBD [ 49 50 Inflammatory mediators and ROS play a critical role in the disruption of tight junction proteins and the subsequent increase in gut permeability that contributes to the progression of ulcerative colitis [ 51 52 53 E. coli 54 We previously reported a decrease in IL‚Äê10 in the proximal colon in DSS with some protection against this decrease for WMP [ 23 46 47 As expected, oxidative stress and lipid peroxidation, indicated by increased levels of MPO and MDA, were elevated following DSS‚Äêinduced colitis compared to controls. WMP pretreatment could significantly mitigate MPO increases and similarly showed a trend suggesting protective effects on MDA levels, in the distal colon compared to DSS. SOD, an antioxidant enzyme that is active in response to ROS, was increased in the distal colon of both groups likely in response to DSS‚Äêinduced ROS production. In the recovery trial, MPO levels in the proximal colon approached those of healthy controls for the WMP group, while the DSS group was still significantly elevated. In the distal colon, we see a similar, though nonsignificant, trend again indicating a faster recovery. No significant differences in MDA or SOD activity were observed across any groups in recovery. These findings suggest that WMP may support intestinal barrier integrity in DSS‚Äêinduced colitis by modulating inflammation and oxidative stress. Previous in vitro studies have demonstrated significant DPPH scavenging ability of methanolic [ 55 56 A. bisporus A. bisporus 56 57 58 To evaluate the potential modulatory effects of WMP on gut microbiota, we performed 16S rRNA sequencing on fecal samples collected from mice across both experimental trials. In the pretreatment trial, we observed a lower Shannon index, indicative of reduced alpha diversity, in the WMP group compared to the DSS group on Day 9. Given that this finding was also observed on Day 0 (data not shown), we believe it to be a cage effect, unrelated to WMP treatment or DSS, as mice were housed according to treatment group. Beta diversity metrics indicated a significant overall difference in microbiome composition across groups at Days 9 and 16. A more detailed taxonomic analysis at the genus level revealed differences in the WMP pretreated group compared to vehicle control, indicating that WMP may selectively influence specific bacterial taxa. These changes were noted at Day 9 only, before DSS administration. There was a significant reduction in the relative abundance of Alphaproteobacteria Allobaculum Parabacteroides Alphaproteobacteria 59 Allobaculum Erysipelotrichaceae Allobaculum 60 61 Allobaculum A. mucolyticum 62 A. mucolyticum 63 Allobaculum Parabacteroides 64 65 66 38 67 5 Conclusion In conclusion, this study demonstrates that WMP from A. bisporus A. bisporus A. bisporus A. bisporus Conflicts of Interest Supriya Yadav and Jude Wilson are employees of MBio, part of Monaghan Mushrooms Group who supplied the powdered mushroom used in this study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Supporting information Supporting file 1: mnfr70133‚Äêsup‚Äê0001‚ÄêSuppMat.docx Acknowledgments The authors thank the Irish Research Council Enterprise Partnership Scheme (Postdoctoral) grant [EPSPD/2022/130] awarded to E.D. and Science Foundation Ireland Frontiers for the Future Programme grant [19/FFP/6499] awarded to S.C.C. for the support. The authors also thank Fiona Crispie and Oksana Mazur at Teagasc Sequencing Centre for carrying out the 16S rRNA sequencing. Data Availability Statement The data that support the findings of this study are available from the authors upon reasonable request. References 1 A. Ahmed G. Mahmoud M. Mohamed Z. Liu C. Ma Overview on the Edible Mushrooms in Egypt Journal of Future Foods 3 2023 8 15 2 A. L. Loyd B. S. Richter M. A. Jusino Identifying the ‚ÄúMushroom of Immortality‚Äù: Assessing the Ganoderma Species Composition in Commercial Reishi Products Frontiers in Microbiology 9 2018 1557 30061872 10.3389/fmicb.2018.01557 PMC6055023 3 P. Ray S. Kundu D. Paul Exploring the Therapeutic Properties of Chinese Mushrooms With a Focus on Their Anti‚Äêcancer Effects: A Systemic Review Pharmacological Research‚ÄîModern Chinese Medicine 11 2024 100433 4 D. E. Nichols Psilocybin: From Ancient Magic to Modern Medicine The Journal of Antibiotics 73 2020 679 686 32398764 10.1038/s41429-020-0311-8 5 S. Zhao Q. Gao C. Rong Immunomodulatory Effects of Edible and Medicinal Mushrooms and Their Bioactive Immunoregulatory Products Journal of Fungi (Basel) 6 2020 269 10.3390/jof6040269 PMC7712035 33171663 6 R. R. Griffiths M. W. Johnson M. A. Carducci Psilocybin Produces Substantial and Sustained Decreases in Depression and Anxiety in Patients With Life‚ÄêThreatening Cancer: A Randomized Double‚ÄêBlind Trial Journal of Psychopharmacology 30 2016 1181 1197 27909165 10.1177/0269881116675513 PMC5367557 7 S. K. Deshmukh V. Prakash N. Ranjan Marine Fungi: A Source of Potential Anticancer Compounds Frontiers in Microbiology 8 2017 2536 29354097 10.3389/fmicb.2017.02536 PMC5760561 8 P. Chowdhury S. Paul The Potential Role of Mushrooms in The Prevention and Treatment of Diabetes: A Review Journal of Biologically Active Products from Nature 10 2020 429 454 9 R. W. Mwangi J. M. Macharia I. N. Wagara R. L. Bence The Antioxidant Potential of Different Edible and Medicinal Mushrooms Biomedicine & Pharmacotherapy 147 2022 112621 35026489 10.1016/j.biopha.2022.112621 10 R. Zara A. Rasul T. Sultana F. Jabeen Z. Selamoglu Identification of Macrolepiota procera Saudi Journal of Biological Sciences 29 2022 3372 3379 35865797 10.1016/j.sjbs.2022.02.018 PMC9295138 11 M. Sevindik H. Akgul Z. Selamoglu N. Braidy Antioxidant, Antimicrobial and Neuroprotective Effects of Octaviania asterosperma Mycology 12 2020 128 138 34035978 10.1080/21501203.2020.1816584 PMC8131004 12 H. Du Y. Han G. Ma Dietary Intake of Whole King Oyster Mushroom ( Pleurotus eryngii Food Research International 184 2024 114228 38609215 10.1016/j.foodres.2024.114228 13 Y. M. Kim H. W. Woo M. H. Shin A Prospective Association Between Dietary Mushroom Intake and the Risk of Type 2 Diabetes: The Korean Genome and Epidemiology Study‚ÄìCardiovascular Disease Association Study Epidemiology and Health 46 2024 2024017 10.4178/epih.e2024017 PMC11040214 38228086 14 D. M. Ba P. Ssentongo R. B. Beelman Higher Mushroom Consumption Is Associated With Lower Risk of Cancer: A Systematic Review and Meta‚ÄêAnalysis of Observational Studies Advances in Nutrition 12 2021 1691 1704 33724299 10.1093/advances/nmab015 PMC8483951 15 M. Li L. Yu J. Zhao Role of Dietary Edible Mushrooms in the Modulation of Gut Microbiota Journal of Functional Foods 83 2021 104538 16 G. Venturella V. Ferraro F. Cirlincione M. L. Gargano Medicinal Mushrooms: Bioactive Compounds, Use, and Clinical Trials International Journal of Molecular Sciences 22 2021 634 33435246 10.3390/ijms22020634 PMC7826851 17 E. W. Lee K. Shizuki S. Hosokawa Two Novel Diterpenoids, Erinacines H and I From the Mycelia of Hericium erinaceum Bioscience, Biotechnology, and Biochemistry 64 2000 2402 2405 11193408 10.1271/bbb.64.2402 18 G. M. Liuzzi T. Petraglia T. Latronico A. Crescenzi R. Rossano Antioxidant Compounds from Edible Mushrooms as Potential Candidates for Treating Age‚ÄêRelated Neurodegenerative Diseases Nutrients 15 2023 1913 37111131 10.3390/nu15081913 PMC10145943 19 R. Sun D. Jin F. Fei Mushroom Polysaccharides From Grifola frondosa Inonotus obliquus Frontiers in Pharmacology 14 2023 1172963 37351508 10.3389/fphar.2023.1172963 PMC10282762 20 M. Blumfield K. Abbott E. Duve Examining the Health Effects and Bioactive Components in Agaricus bisporus The Journal of Nutritional Biochemistry 84 2020 108453 32653808 10.1016/j.jnutbio.2020.108453 21 G. Cardwell J. F. Bornman A. P. James L. J. Black A Review of Mushrooms as a Potential Source of Dietary Vitamin D Nutrients 10 2018 1498 30322118 10.3390/nu10101498 PMC6213178 22 S. Yadav J. Wilson M. Mushrooms Antioxidant and Ergothioneine Assessment of Nutritionally Enriched Agaricus bisporus EC Nutrition 17 2022 63 80 23 M. O'Sullivan E. Dempsey S. Case Negative Regulation of Innate Immune Signaling by Components of the Button Mushroom Agaricus bisporus Molecular Nutrition & Food Research 67 2023 2200845 10.1002/mnfr.202200845 37195234 24 S. Case T. O'Brien A. E. Ledwith Œ≤‚ÄêGlucans From Agaricus bisporus Frontiers in Nutrition 11 2024 1346706 38425482 10.3389/fnut.2024.1346706 PMC10902450 25 B. Muszynska A. Grzywacz K. Kala J. Gdula‚ÄêArgasinska Anti‚ÄêInflammatory Potential of In Vitro Cultures of the White Button Mushroom, Agaricus bisporus International Journal of Medicinal Mushrooms 20 2018 129 139 29773005 10.1615/IntJMedMushrooms.2018025408 26 K. Kohno M. Miyake O. Sano Anti‚ÄêInflammatory and Immunomodulatory Properties of 2‚ÄêAmino‚Äê3H‚Äêphenoxazin‚Äê3‚Äêone Biological and Pharmaceutical Bulletin 31 2008 1938 1945 18827359 10.1248/bpb.31.1938 27 C. Moro I. Palacios M. Lozano Anti‚ÄêInflammatory Activity of Methanolic Extracts From Edible Mushrooms in LPS Activated RAW 264.7 Macrophages Food Chemistry 130 2012 350 355 28 W. Liu L. Wang Q. Yuan  Agaricus bisporus Journal of Inflammation Food & Function 15 2024 1191 1207 10.1039/d3fo04430k 38230753 29 K. Hsia N. Zhao M. Chung Alterations in the Fungal Microbiome in Ulcerative Colitis Inflammatory Bowel Diseases 29 2023 1613 1621 37221272 10.1093/ibd/izad082 PMC10547232 30 A. N. Ananthakrishnan G. G. Kaplan S. C. Ng Changing Global Epidemiology of Inflammatory Bowel Diseases: Sustaining Health Care Delivery into the 21st Century Clinical Gastroenterology and Hepatology 18 2020 1252 1260 32007542 10.1016/j.cgh.2020.01.028 31 F. C. Ross D. Patangia G. Grimaud The Interplay Between Diet and the Gut Microbiome: Implications for Health and Disease Nature Reviews Microbiology 22 2024 671 686 39009882 10.1038/s41579-024-01068-4 32 V. Jairath B. G. Feagan Global Burden of Inflammatory Bowel Disease The Lancet Gastroenterology & Hepatology 5 2020 2 3 31648974 10.1016/S2468-1253(19)30358-9 33 R. Mishra P. Dhawan A. S. Srivastava A. B. Singh Inflammatory Bowel Disease: Therapeutic Limitations and Prospective of the Stem Cell Therapy World Journal of Stem Cells 12 2020 1050 1066 33178391 10.4252/wjsc.v12.i10.1050 PMC7596447 34 A. O'Connor A. Qasim C. A. O'Mor√°in The Long‚ÄêTerm Risk of Continuous Immunosuppression Using Thioguanides in Inflammatory Bowel Disease Therapeutic Advances in Chronic Disease 1 2010 7 16 23251725 10.1177/2040622310368736 PMC3513853 35 H. Gordon L. Biancone G. Fiorino ECCO Guidelines on Inflammatory Bowel Disease and Malignancies Journal of Crohn's and Colitis 17 2023 827 854 10.1093/ecco-jcc/jjac187 36528797 36 A. Dowley T. Sweeney E. Conway The Effects of Dietary Supplementation With Mushroom or Vitamin D2 Enriched Mushroom Powders on Finisher Pig Performance and Meat Quality Animal Feed Science and Technology 288 2022 115313 37 B. G. Postal D. Aguanno S. Thenet V. Carri√®re Rapid Evaluation of Intestinal Paracellular Permeability Using the Human Enterocytic‚ÄêLike Caco‚Äê2/TC7 Cell Line Methods in Molecular Biology 2367 2021 13 26 33730353 10.1007/7651_2021_366 38 I. Okayasu S. Hatakeyama M. Yamada A Novel Method in the Induction of Reliable Experimental Acute and Chronic Ulcerative Colitis in Mice Gastroenterology 98 1990 694 702 1688816 10.1016/0016-5085(90)90290-h 39 D. G. W. Johnston M. A. Williams C. A. Thaiss Loss of MicroRNA‚Äê21 Influences the Gut Microbiota, Causing Reduced Susceptibility in a Murine Model of Colitis Journal of Crohn's and Colitis 12 2018 835 848 10.1093/ecco-jcc/jjy038 29608690 40 P. Bankhead M. B. Loughrey J. A. Fern√°ndez QuPath: Open Source Software for Digital Pathology Image Analysis Scientific Reports 7 2017 16878 29203879 10.1038/s41598-017-17204-5 PMC5715110 41 E. Bolyen J. R. Rideout M. R. Dillon Reproducible, Interactive, Scalable and Extensible Microbiome Data Science Using QIIME 2 Nature Biotechnology 37 2019 852 857 10.1038/s41587-019-0209-9 PMC7015180 31341288 42 D. McDonald M. N. Price J. Goodrich An Improved Greengenes Taxonomy With Explicit Ranks for Ecological and Evolutionary Analyses of Bacteria and Archaea The ISME Journal 6 2012 610 618 22134646 10.1038/ismej.2011.139 PMC3280142 43 P. P. Bradley D. A. Priebat R. D. Christensen G. Rothstein Measurement of Cutaneous Inflammation: Estimation of Neutrophil Content With an Enzyme Marker Journal of Investigative Dermatology 78 1982 206 209 6276474 10.1111/1523-1747.ep12506462 44 S. Yu Y. Sun X. Shao Leaky Gut in IBD: Intestinal Barrier‚ÄìGut Microbiota Interaction Journal of Microbiology and Biotechnology 32 2022 825 834 35791076 10.4014/jmb.2203.03022 PMC9628915 45 H. Li J. Feng C. Liu Polysaccharides From an Edible Mushroom, Hericium Erinaceus, Alleviate Ulcerative Colitis in Mice by Inhibiting the NLRP3 Inflammasomes and Reestablish Intestinal Homeostasis International Journal of Biological Macromolecules 267 2024 131251 38556226 10.1016/j.ijbiomac.2024.131251 46 Z.‚ÄêH. Ji S. He W.‚ÄêY. Xie Nutrients 2023 47 M. Y. Zou Y. J. Wang Y. Liu Huangshan Floral Mushroom Polysaccharide Ameliorates Dextran Sulfate Sodium‚ÄêInduced Colitis in Mice by Modulating Th17/Treg Balance in a Gut Microbiota‚ÄêDependent Manner Molecular Nutrition & Food Research 67 2023 2200408 10.1002/mnfr.202200408 36418892 48 K. R. Groschwitz S. P. Hogan Intestinal Barrier Function: Molecular Regulation and Disease Pathogenesis Journal of Allergy and Clinical Immunology 124 2009 3 20 19560575 10.1016/j.jaci.2009.05.038 PMC4266989 49 S. H. Lee Intestinal Permeability Regulation by Tight Junction: Implication on Inflammatory Bowel Diseases Intestinal Research 13 2015 11 18 25691839 10.5217/ir.2015.13.1.11 PMC4316216 50 W. T. Kuo L. Shen L. Zuo Inflammation‚ÄêInduced Occludin Downregulation Limits Epithelial Apoptosis by Suppressing Caspase‚Äê3 Expression Gastroenterology 157 2019 1323 1337 31401143 10.1053/j.gastro.2019.07.058 PMC6815722 51 J. Landy E. Ronde N. English Tight Junctions in Inflammatory Bowel Diseases and Inflammatory Bowel Disease Associated Colorectal Cancer World Journal of Gastroenterology 22 2016 3117 3126 27003989 10.3748/wjg.v22.i11.3117 PMC4789987 52 M. Sasaki J. M. Mathis M. H. Jennings Reversal of Experimental Colitis Disease Activity in Mice Following Administration of an Adenoviral IL‚Äê10 Vector Journal of Inflammation (Lond) 2 2005 13 10.1186/1476-9255-2-13 PMC1291390 16259632 53 T. Jofra G. Galvani I. Cosorich Experimental Colitis in IL‚Äê10‚ÄêDeficient Mice Ameliorates in the Absence of PTPN22 Clinical and Experimental Immunology 197 2019 263 275 31194881 10.1111/cei.13339 PMC6693971 54 D. F. Zegarra Ruiz D. V. Kim K. Norwood Microbiota Manipulation to Increase Macrophage IL‚Äê10 Improves Colitis and Limits Colitis‚ÄêAssociated Colorectal Cancer Gut Microbes 14 2022 2119054 36062329 10.1080/19490976.2022.2119054 PMC9450902 55 M. Elmastas O. Isildak I. Turkekul N. Temur Determination of Antioxidant Activity and Antioxidant Compounds in Wild Edible Mushrooms Journal of Food Composition and Analysis 20 2007 337 345 56 J. Liu L. Jia J. Kan C.‚Äêh. Jin In Vitro and In Vivo Antioxidant Activity of Ethanolic Extract of White Button Mushroom ( Agaricus bisporus Food and Chemical Toxicology 51 2013 310 316 23099505 10.1016/j.fct.2012.10.014 57 Y. Ren Y. Geng Y. Du Polysaccharide of Hericium Erinaceus Attenuates Colitis in C57BL/6 Mice via Regulation of Oxidative Stress, Inflammation‚ÄêRelated Signaling Pathways and Modulating the Composition of the Gut Microbiota The Journal of Nutritional Biochemistry 57 2018 67 76 29677563 10.1016/j.jnutbio.2018.03.005 58 Y. Zhang F. Lu H. Zhang Polysaccharides From Agaricus blazei Murrill Journal of Functional Foods 92 2022 105072 59 J. Castro‚ÄêMej√≠a M. Jakesevic ≈Å. Krych Treatment With a Monoclonal Anti‚ÄêIL‚Äê12p40 Antibody Induces Substantial Gut Microbiota Changes in an Experimental Colitis Model Gastroenterology Research and Practice 2016 2016 4953120 26880890 10.1155/2016/4953120 PMC4736578 60 L. M. Cox S. Yamanishi J. Sohn Altering the Intestinal Microbiota During a Critical Developmental Window Has Lasting Metabolic Consequences Cell 158 2014 705 721 25126780 10.1016/j.cell.2014.05.052 PMC4134513 61 E. Miyauchi S. W. Kim W. Suda Gut Microorganisms Act Together to Exacerbate Inflammation in Spinal Cords Nature 585 2020 102 106 32848245 10.1038/s41586-020-2634-9 62 N. W. Palm M. R. de Zoete T. W. Cullen Immunoglobulin A Coating Identifies Colitogenic Bacteria in Inflammatory Bowel Disease Cell 158 2014 1000 1010 25171403 10.1016/j.cell.2014.08.006 PMC4174347 63 G. H. van Muijlwijk G. van Mierlo P. Jansen Identification of Allobaculum mucolyticum Gut Microbes 13 2021 1966278 34455931 10.1080/19490976.2021.1966278 PMC8409761 64 J. C. Ezeji D. K. Sarikonda A. Hopperton  Parabacteroides distasonis Gut Microbes 13 2021 1922241 34196581 10.1080/19490976.2021.1922241 PMC8253142 65 M. Kverka Z. Zakostelska K. Klimesova Oral Administration of Parabacteroides distasonis Clinical and Experimental Immunology 163 2011 250 259 21087444 10.1111/j.1365-2249.2010.04286.x PMC3043316 66 B. Cuffaro A. L. W. Assohoun D. Boutillier In Vitro Characterization of Gut Microbiota‚ÄêDerived Commensal Strains: Selection of Parabacteroides distasonis Cells 9 2020 2104 32947881 10.3390/cells9092104 PMC7565435 67 A. Mendes‚ÄêFrias M. Moreira M. C. Vieira  Akkermansia muciniphila Parabacteroides distasonis Frontiers in Cellular and Infection Microbiology 14 2024 1367998 39027140 10.3389/fcimb.2024.1367998 PMC11254828 ",
  "metadata": {
    "Title of this paper": "\n",
    "Journal it was published in:": "Molecular Nutrition & Food Research",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490186/"
  }
}